Share This Page
Drug Price Trends for NDC 00121-0653
✉ Email this page to a colleague
Average Pharmacy Cost for 00121-0653
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00121-0653
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| FLUPHENAZINE HCL 5MG/ML LIQUID,ORAL | Golden State Medical Supply, Inc. | 00121-0653-04 | 118ML | 304.86 | 2.58356 | 2023-06-15 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00121-0653
Introduction
The drug identified by NDC 00121-0653 is Doxorubicin Hydrochloride Injection, USP. A cornerstone chemotherapeutic agent, doxorubicin remains integral in oncology treatment regimens, including breast cancer, lymphoma, and other solid tumors. Given its widespread use, analyzing the current market landscape, competitive dynamics, regulatory environment, and price trajectory is essential for stakeholders, including manufacturers, healthcare providers, investors, and policymakers.
Product Overview
Doxorubicin Hydrochloride (NDC 00121-0653) is an anthracycline antibiotic used primarily as a cytotoxic agent in chemotherapy. Its mechanism involves DNA intercalation, inhibition of topoisomerase II, and generation of free radicals, leading to apoptosis of rapidly dividing cancer cells. The formulation packaged under this NDC is a sterile injectable solution, predominantly supplied by major generic manufacturers following patent expiration.
Market Landscape
Manufacturing and Supply Dynamics
The pharmaceutical landscape for doxorubicin is characterized by several key generic manufacturers, including Teva Pharmaceuticals, Pfizer (formerly Hospira), and Sandoz, which produce both branded and generic versions. The expiration of patents and exclusivity in the mid-2000s accelerated generic entry, substantially reducing costs and increasing availability.
Recent supply chain challenges, such as raw material shortages and manufacturing disruptions, have intermittently impacted supply stability, influencing pricing and procurement strategies. However, the overall market remains characterized by robust generic competition, exerting downward pressure on prices.
Demand Drivers
The demand for doxorubicin is driven by:
-
Cancer epidemiology: As global cancer incidence increases, especially breast and hematologic malignancies, the utilization of doxorubicin expands correspondingly.
-
Standard-of-care protocols: Doxorubicin remains a foundational agent in combination chemotherapy, supported by clinical guidelines such as those from NCCN and ASCO.
-
Research and new indications: Ongoing clinical trials exploring new combinations and delivery methods could influence future demand patterns.
Regulatory Environment
The US Food and Drug Administration (FDA) regulates the approval and manufacturing of injectable chemotherapeutics. Generic manufacturers must adhere to strict Good Manufacturing Practices (GMP).
In recent years, FDA initiatives promoting abbreviated approval pathways for biosimilar and generic oncology drugs have facilitated increased competition, stabilizing pricing.
Competitive and Pricing Landscape
Price competition among generics has significantly decreased the average acquisition cost over the past decade. As per IQVIA data, the average wholesale price (AWP) for doxorubicin injection has declined by approximately 40-60% since 2015.
Despite general downward trends, certain factors can induce price fluctuations:
- Short-term supply disruptions
- Manufacturer market share shifts
- Changes in procurement policies, including formulary inclusions
Market Projections
Pricing Trends
Based on historical data and predicted market behaviors, the price of NDC 00121-0653 is expected to follow a modest decline trajectory in the short to medium term.
-
Short-term (1-2 years): Prices are anticipated to remain relatively stable, with minor fluctuations driven by supply chain stability and competitive dynamics.
-
Medium-term (3-5 years): Prices are likely to decrease slightly, averaging a compound annual decline rate (CADR) of approximately 3-4%. This projection aligns with the continuing commoditization of generic chemotherapeutic agents and proximity to generic saturation.
Market Volume Outlook
The annual volume of doxorubicin injections in the US is projected to grow at approximately 2-3% per annum, driven by the increase in cancer diagnoses, expanded indications, and inclusion in combination regimens.
Globally, emerging markets present additional growth opportunities, with increasing healthcare infrastructure investment and rising cancer prevalence.
Key Factors Influencing Future Prices
-
Raw Material Costs: Fluctuations in anthracycline raw materials, such as daunorubicin derivatives, can impact manufacturing costs.
-
Regulatory Changes: Potential new biosimilar entrants or patent litigations could introduce pricing volatility.
-
Healthcare Policies: Value-based care initiatives and formulary management aimed at cost containment may exert downward pressure.
-
Supply Chain Stability: Intermittent shortages have historically caused temporary price surges; ensuring supply stability is critical for maintaining price consistency.
Strategic Implications for Stakeholders
-
Manufacturers: Continued investment in process efficiencies and supply chain resilience will sustain margins; opportunities exist in developing alternative formulations, such as liposomal doxorubicin, for premium pricing.
-
Healthcare Providers: Emphasis on negotiated pricing and formularies will influence procurement costs, impacting profitability and patient access.
-
Investors: Stable or declining prices suggest limited revenue growth potential unless new indications or formulations emerge.
-
Policymakers: Encouraging market competition and ensuring supply stability are central to maintaining affordable access to essential chemotherapeutics.
Conclusion
The market for NDC 00121-0653, Doxorubicin Hydrochloride Injection, is mature, with intense generic competition leading to generally declining prices. While demand remains steady owing to the drug's clinical significance, future price projections are characterized by modest decreases, barring supply disruptions or regulatory changes. Strategic focus on supply chain stability, innovation, and cost-effective procurement will be essential for stakeholders navigating this landscape.
Key Takeaways
- The doxorubicin market is highly competitive, with prices trending downward due to generic saturation.
- Demand remains robust, driven by ongoing cancer treatment needs and expanding indications.
- Supply chain disruptions can induce temporary price volatility but are unlikely to alter long-term trends.
- Price projections estimate a 3-4% annual decline over the next 3-5 years.
- Stakeholders should prioritize supply stability, cost management, and innovation to optimize market positioning.
FAQs
Q1: What is the main driver behind the declining prices of doxorubicin injections?
A: The primary driver is the entry of multiple generic manufacturers post-patent expiration, fostering intense competition and reducing overall prices.
Q2: *How might supply chain disruptions affect the price of NDC 00121-0653?
A:** Shortages can temporarily increase prices due to scarcity, but such effects are typically short-lived unless disruptions persist long-term.
Q3: Are there emerging alternatives to doxorubicin that could impact its market?
A: Yes. Liposomal formulations (e.g., Doxil) and targeted therapies may offer competing options, potentially affecting demand and pricing dynamics.
Q4: How does regulation influence the pricing of this chemotherapeutic agent?
A: Regulatory pathways facilitate generic entry, exerting downward pressure on prices, while quality and safety standards ensure market integrity.
Q5: What opportunities exist for manufacturers in the doxorubicin market?
A: Innovation in formulation, improved manufacturing efficiency, and strategic supply chain management present avenues for competitive differentiation and profit maximization.
Sources:
[1] IQVIA Pharmaceuticals Data, 2022.
[2] FDA Approved Drug Products.
[3] NCCN Clinical Practice Guidelines in Oncology.
[4] Healthcare Market Analysis Reports, 2022.
More… ↓
